Skip to content

MEDICINOVA, INC.: 10-Q filed 2018-10-25

What MEDICINOVA, INC. reported in its quarterly report filed 2018-10-25 (fiscal Q3 2018): 31 published measures, 82 facts as tagged in accession 0001564590-18-025127.

This filing

Form
10-Q (quarterly report)
Filed
2018-10-25
Fiscal period
fiscal Q3 2018
Accession
0001564590-18-025127 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MEDICINOVA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-09-3077,275,331USD
At 2017-12-3143,419,064USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-09-303,723,560USD
At 2017-12-314,776,924USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-09-3073,551,771USD
At 2017-12-3138,642,140USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-09-3062,442,366USD
At 2017-12-3127,991,743USD
At 2017-09-3024,535,427USD
At 2016-12-3124,118,037USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-6,779,958USD92
2018-01-01 to 2018-09-30-14,467,148USD273
2017-07-01 to 2017-09-30-3,755,103USD92
2017-01-01 to 2017-09-30-9,560,265USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-09-30-7,470,358USD273
2017-01-01 to 2017-09-30-5,877,954USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-09-3010,207USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-09-3041,293,677USD273
2017-01-01 to 2017-09-306,294,475USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-09-30626,317USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-09-30-355,923,348USD
At 2017-12-31-341,456,200USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-07-01 to 2018-09-301,663USD92
2018-01-01 to 2018-09-303,570USD273
2017-07-01 to 2017-09-302,054USD92
2017-01-01 to 2017-09-308,144USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-09-3053,327USD
At 2017-12-3162,886USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-07-01 to 2018-09-304,700,000USD92
2018-01-01 to 2018-09-308,081,897USD273
2017-07-01 to 2017-09-301,500,000USD92
2017-01-01 to 2017-09-303,451,807USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-7,027,714USD92
2018-01-01 to 2018-09-30-15,094,577USD273
2017-07-01 to 2017-09-30-3,791,536USD92
2017-01-01 to 2017-09-30-9,620,047USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-09-3062,810,806USD
At 2017-12-3128,328,323USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-09-301,804,514USD
At 2017-12-312,880,969USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-09-30608,282USD
At 2017-12-311,520,225USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-09-309,600,240USD
At 2017-12-319,600,240USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-07-01 to 2018-09-307,027,714USD92
2018-01-01 to 2018-09-3015,094,577USD273
2017-07-01 to 2017-09-303,791,536USD92
2017-01-01 to 2017-09-309,620,047USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-07-01 to 2018-09-302,300,000USD92
2018-01-01 to 2018-09-305,200,000USD273
2017-07-01 to 2017-09-301,200,000USD92
2017-01-01 to 2017-09-302,900,000USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-09-3041,881,306shares
At 2017-12-3136,452,893shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-09-30-93,418USD
At 2017-12-31-94,623USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-09-3010,958USD
At 2017-12-3110,958USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-09-301,196,232USD
At 2017-12-311,360,744USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-09-30368,440USD
At 2017-12-31336,580USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-6,778,295USD92
2018-01-01 to 2018-09-30-14,463,578USD273
2017-07-01 to 2017-09-30-3,753,049USD92
2017-01-01 to 2017-09-30-9,552,121USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-01-01 to 2018-09-30-14,467,148USD273
2017-01-01 to 2017-09-30-9,560,265USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-6,780,570USD92
2018-01-01 to 2018-09-30-14,465,943USD273
2017-07-01 to 2017-09-30-3,754,592USD92
2017-01-01 to 2017-09-30-9,558,538USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-07-01 to 2018-09-304,657,679USD92
2018-01-01 to 2018-09-309,683,242USD273
2017-07-01 to 2017-09-302,523,119USD92
2017-01-01 to 2017-09-306,553,760USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2018-01-01 to 2018-09-3019,768USD273
2017-01-01 to 2017-09-3021,452USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-19,018USD92
2018-01-01 to 2018-09-30-19,014USD273
2017-07-01 to 2017-09-30-3,309USD92
2017-01-01 to 2017-09-30-13,783USD273

Inspect the source

Entity
MEDICINOVA, INC. / CIK 0001226616
Captured
2026-09-20T07:46:14.294Z
SEC response SHA-256
2ee4e761c5c78942e5c8408ca3fc8acae481ff5fcfadf88ffba53700bd842714

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001226616.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))